Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,358 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ. Yang DH, et al. Among authors: ahn js. Ann Hematol. 2009 May;88(5):425-32. doi: 10.1007/s00277-008-0616-3. Epub 2008 Nov 12. Ann Hematol. 2009. PMID: 19002686 Clinical Trial.
Polymyositis and myocarditis after donor lymphocyte infusion.
Ahn JS, Cho SH, Kim YK, Yang DH, Bae WK, Shim HJ, Lee JJ, Chung IJ, Juhng SW, Kim HJ. Ahn JS, et al. Int J Hematol. 2009 Jul;90(1):113-116. doi: 10.1007/s12185-009-0332-3. Epub 2009 May 27. Int J Hematol. 2009. PMID: 19472035
Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY, Lee JH, Lee JH, Lee KH, Kim YK, Ahn JS, Kim HJ, Kim I, Yoon SS, Park S, Bae SH, Bang SM, Lee HG, Shin HJ, Lee JH, Min YH, Won JH, Mun YC, Oh D; Korean Society of Hematology AML/MDS Working Party. Kim DY, et al. Among authors: ahn js. Ann Hematol. 2010 Jan;89(1):15-23. doi: 10.1007/s00277-009-0771-1. Epub 2009 Jun 19. Ann Hematol. 2010. PMID: 19543727
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP). Kim YK, et al. Among authors: ahn js. Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18. Ann Hematol. 2010. PMID: 19921192 Clinical Trial.
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.
Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, Choi YJ, Lee WS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party. Yang DH, et al. Among authors: ahn js. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):62-7. doi: 10.3816/CLML.2010.n.007. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20223731 Clinical Trial.
1,358 results